Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine

Phase 3

Completed

• Conditions: Poliomyelitis
• Interventions: Biological: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A; Biological: Sii Licensed IPV; Biological: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B; Biological: SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C

• Registration Number: NCT05163561
• Lead Sponsor: Serum Institute of India Pvt. Ltd.

Brief Summary

This Phase III study has been designed to compare the SII Inactivated Salk Polio Vaccine (Adsorbed) with Sii licensed IPV by testing the vaccine in infants (three doses administered 4 weeks apart, starting at 6-8 weeks of age) in order to demonstrate the non-inferiority in the induction of specific poliovirus neutralizing antibody (PVNA) to poliovirus type 1, type 2 and type 3 by these vaccines. The study will also evaluate lot-to-lot consistency in the manufacture of SII Inactivated Salk Polio Vaccine (Adsorbed) by demonstrating equivalence in the induction of PVNA across three production lots.

Detailed Description

The study is designed as a double-blind, randomized, active-controlled Phase III study with four groups of infants (n=268 per group) receiving either SII Inactivated Salk Polio Vaccine (Adsorbed) from the three lots or Sii licensed IPV.

Participants will be screened for eligibility with their parental consent and will be selected for the study according to inclusion and exclusion criteria. A total of 1072 participants will be enrolled.

Following vaccination, enrolled participants will remain in the clinic for at least 30 minutes for observation. During this time, they will be closely monitored for any immediate adverse events. Safety will be evaluated by active surveillance for solicited adverse events over the 4-day period after each vaccination in all participants. In addition, surveillance for unsolicited AEs and SAEs will be carried out over the period from first vaccination and 28 days after the third vaccination in all participants.

The immunogenicity will be assessed by measuring the PVNA to poliovirus type 1, type 2 and type 3 using a standardized microneutralization test in the sera samples of the participants.

Study Timeline

• Study First Submitted: 2021-12-03
• Study First Submitted QC: 2021-12-17
• Study First Posted: 2021-12-20
• Study Start: 2022-01-09
• Primary Completion: 2023-04-29
• Study Completion: 2023-04-29
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-20
• Last Update Posted: 2023-10-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1072

Inclusion Criteria

1. Healthy infants as established by medical history and clinical examination before entering the study
2. Age: 6-8 weeks at the time of enrolment
3. Parental ability and willingness to provide informed consent
4. Parent who intends to reside in the area with the infant during the study period

Exclusion Criteria

1. Presence of fever on the day of enrolment [Temporary exclusion criteria].
2. Acute disease at the time of enrolment [Temporary exclusion criteria].
3. Prior receipt or intent to receive OPV/IPV/IPV containing vaccines during the study period.
4. OPV vaccination or known exposure to poliovirus (wild or vaccine derived) in household (living together) within 3-months prior to inclusion or planned during the study.
5. Presence of significant malnutrition (weight-for-height z-score < -3SD median)
6. Known or suspected impairment of immunological function based on medical history and physical examination.
7. Presence of any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, immunological, dermatological, neurological, cancer, or autoimmune disease) as determined by medical history and / or physical examination which would compromise the participant's health or is likely to result in nonconformance to the protocol.
8. A known sensitivity or allergy to any components of the Investigational Product.
9. Receipt of immunoglobulin therapy and / or blood products since birth or planned administration during the study period
10. Planned concurrent participation in another clinical study at any point throughout the entire study period

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SII Inactivated Salk Polio Vaccine (Adsorbed) Lot A	SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A	SII Inactivated Salk Polio Vaccine (Adsorbed) Lot A
Sii Licensed IPV	Sii Licensed IPV	Sii Licensed IPV
SII Inactivated Salk Polio Vaccine (Adsorbed) Lot B	SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B	SII Inactivated Salk Polio Vaccine (Adsorbed) Lot B
SII Inactivated Salk Polio Vaccine (Adsorbed) Lot C	SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C	SII Inactivated Salk Polio Vaccine (Adsorbed) Lot C

Primary Outcome Measures

Name	Time	Method
Percentage of participants with type-specific seroconversion	Day 28 after third vaccination	Percentage of participants with type-specific seroconversion\* on Day 28 after the third vaccination for SII Inactivated Salk Polio Vaccine (Adsorbed) and Sii Licensed IPV

Secondary Outcome Measures

Name	Time	Method
Reverse cumulative distribution curves of antibody titers	pre-vaccination and 28 days after third vaccination	Type-specific reverse cumulative distribution curves of antibody titers on pre-vaccination and 28 days after third vaccination of three cGMP lots of SII Inactivated Salk Polio Vaccine (Adsorbed) and Sii Licensed IPV.
Percentage of participants with type-specific seroprotection	Day 28 after the third vaccination	Percentage of participants with type-specific seroprotection (titers ≥ 8) on Day 28 after the third vaccination of three cGMP lots of SII Inactivated Salk Polio Vaccine (Adsorbed) and Sii Licensed IPV.
Geometric Mean Titers	Day 28 after third vaccination	Type-specific geometric mean titers on day 28 after the third vaccination of three cGMP lots of SII Inactivated Salk Polio Vaccine (Adsorbed) and Sii Licensed IPV.
Percentage of participants with type-specific post-vaccination titers ≥ 4-fold above the estimated titer of maternal antibody	Day 28 after the third vaccination	Percentage of participants with type-specific post-vaccination titers ≥ 4-fold above the estimated titer of maternal antibody on day 28 after the third vaccination of three cGMP lots of SII Inactivated Salk Polio Vaccine (Adsorbed) and Sii Licensed IPV.

Trial Locations

Locations (1)

International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B); 🇧🇩 Dhaka, Bangladesh